SMYD2 and neoplasm: SMYD2 protein expression levels were determined by immunohistochemistry in a cohort of 147 primary gastric cancer samples and its overexpression significantly correlated with features that influence patient survival, such as lymph node metastasis, larger tumor size and depth of tumor invasion [31].